Importantly, our group has shown that steady‐state levels of 5LO are increased in brain cortices from subjects with a postmortem diagnosis of PSP and that pharmacological inhibition of its activity ameliorates tau pathology and behavioral deficits in the htau mice (Giannopoulos et al., 2015b). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.